CANNABIS DEPENDENCE
Its Nature, Consequences, and Treatment

Cannabis dependence is controversial. Does it occur or is it a myth put forth by those who oppose legalization? What are the signs of cannabis dependence? How many people are affected? What are the health and behavioral risks of becoming cannabis dependent? What counseling approaches have been tested with adults and adolescents, and how effective are they? What are the arguments for legalization, regulation, or prohibition? Looking back and toward the future, what do we know and what do we need to learn?

This state of the science review sets out to answer all those questions, beginning with an historical examination and moving into diagnosis, classification, epidemiology, public health, policy, issues relating to regulation and prohibition, and evidence-based interventions.

ROGER A. ROFFMAN is a Professor of Social Work at the University of Washington. Along with Robert Stephens he has conducted a series of controlled trials to investigate the efficacy of behavioral interventions with adult and adolescent cannabis users. His research also focuses on HIV prevention with several populations and early intervention with perpetrators of domestic violence.

ROBERT S. STEPHENS is an Associate Professor of Psychology at Virginia Tech. His work includes collaborations with Roger A. Roffman on the treatment of cannabis dependence, research on social cognitive determinants of drinking and drug use, and behavioral interventions to improve substance abuse treatment aftercare attendance.
INTERNATIONAL RESEARCH MONOGRAPHS IN THE ADDICTIONS
(IRMa)

Series Editor
Professor Griffith Edwards
National Addiction Centre
Institute of Psychiatry, London

Volumes in this series present important research from major centers around the world on the basic sciences, both biological and behavioral, that have a bearing on the addictions. They also address the clinical and public health applications of such research. The series will cover alcohol, illicit drugs, psychotropics, and tobacco. It is an important resource for clinicians, researchers, and policy-makers.

Also in this series
Cannabis and Cognitive Functioning
Nadia Solowij
ISBN 0 521 159114 7

A Community Reinforcement Approach to Addiction Treatment
Robert J. Meyers and William R. Miller
ISBN 0 521 77107 2

Circles of Recovery: Self-help Organizations for Addictions
Keith N. Humphreys
ISBN 0 521 79299 0

Alcohol and the Community: A Systems Approach to Prevention
Harold D. Holder
ISBN 0 521 59187 2

Treatment Matching in Alcoholism
Thomas F. Babor and Frances K. Del Boca
ISBN 0 521 65112 3

Gambling as an Addictive Behaviour: Impaired Control, Harm Minimization, Treatment, and Prevention
Mark Dickerson and John O’Connor
ISBN 0 521 84701 X
CANNabis DEPENDENCE

Its Nature, Consequences, and Treatment

Edited by

ROGER A. ROFFMAN
Innovative Programs Research Group
University of Washington School of Social Work

ROBERT S. STEPHENS
Department of Psychology
Virginia Polytechnic Institute and State University

Foreword by

G. ALAN MARLATT
Dedication

To my wife, Cheryl Richey, for her love, friendship, and support.

R.A.R.

To my wife, Amy Forsyth-Stephens, for endless amounts of patience and support, and for always believing in me.

R.S.S.
The old orchid hunter lay back on his pillow, his body limp with the effort of talking so long. He coughed and a ripple of pain ran through the wasted length of him beneath the covers. Still his eyes burned unwaveringly bright with the memory of the places he had seen and the things he had done, bright with an unquenchable passion for the life he would never suffer or enjoy again.

“You’ll curse the insects,” he said at last, “and you’ll curse the natives. Your lips will crack and you’ll lick them and taste the salt of your own sweat. The sun will burn you by day and the cold will shrivel you by night. You’ll be racked by fever and tormented by a hundred discomforts, but you’ll go on. For when a man falls in love with orchids, he’ll do anything to possess the one he wants. It’s like chasing a green-eyed woman or taking cocaine. A sort of madness....”

Prologue to:

Norman MacDonald
The Orchid Hunters: A Jungle Adventure
New York: Farrar & Rinehart
1939

Printed in the USA by Quinn & Boden Company, Inc., Rahway, N.J.
Contents

List of Contributors xv
Acknowledgments xviii
Executive Summary xx
Foreword xxvi

Part I: The Nature of Cannabis Dependence
1 Themes in the History of Cannabis Dependence

ROGER A. ROFFMAN, SAM SCHWARTZ AND ROBERT S. STEPHENS

Diversity of Cannabis Preparations 4
The Influence of Tales, Legend, Myth, and Lore 5
Memoirs and Writings of Key Literary Figures and Artists 7
Commissions of Inquiry Concerning Cannabis Dependence 7
  The 1925 Panama Canal Zone Report 9
  The 1929 Preliminary Report on Indian Hemp and Peyote issued by US Surgeon General Hugh S. Cummings 9
  The 1944 LaGuardia Committee Report (“The Marihuana Problem in the City of New York”) 10
  The 1972 Report of the National Commission on Marihuana and Drug Abuse 13
Understanding Cannabis Dependence and Withdrawal by Studying Cannabinoid Neurochemistry 14
Specifying Cannabis Dependence through Classification and Diagnosis 15
Determining the Prevalence of Cannabis Dependence through Epidemiological Research 16
Addressing the Need for Cannabis Dependence Interventions 17

vii
## 2 The Diagnosis of Cannabis Dependence

**THOMAS F. BABOR**

**Introduction** 21  
Nature of the Syndrome 21  
Classification 22  
Diagnosis 24  
   - ICD-10 25  
   - DSM-IV 27  
Evidence for Cannabis Dependence, Including Tolerance and Withdrawal 27  
Etiology, Course and Natural History 30  
Measurement of Cannabis Dependence 31  
Conclusion 33  
References 33

## 3 Understanding the Pharmacology and Physiology of Cannabis Dependence

**ARON H. LICHTMAN AND BILLY R. MARTIN**

Basic Neuropharmacology of Cannabis Effects and the Existence of an Endocannabinoid System 37  
Characterization of Cannabis Dependence 38  
   - Overview 38  
   - Clinical Significance of Cannabis Withdrawal Symptoms 39  
   - Abrupt Cannabinoid Withdrawal in Laboratory Animals 41  
   - Precipitated Cannabinoid Withdrawal in Cannabinoid-Dependent Animals 41  
   - Cannabinoid Self-Administration 44  
   - Neurochemical Mechanisms Underlying Cannabis Dependence 45  
      - CB1 Cannabinoid Receptor Mechanisms of Action 45  
      - Neuroadaptive Changes Underlying Cannabinoid Dependence 46  
      - Interrelationships with Other Neurochemical Systems 47  
Reciprocal Roles of the Cannabinoid and Opioid Systems in Dependence 48  
   - Cannabinoid Systems Modulate Opioid Dependence 48  
   - Opioid Systems Modulate Cannabinoid Dependence 49  
Implications of Animal Studies for Understanding Human Dependence 50  
References 50
4 The Epidemiology of Cannabis Dependence

JAMES C. ANTHONY

Introduction 58
Epidemiology’s Contribution to Nosological Studies of Cannabis Dependence 59
How Many Are Becoming Affected, with Focus on the USA? 64
Where Are We More or Less Likely to Find Cases of Cannabis Dependence? 69
Variation In Relation to Geography and Geopolitical Location 70
Variation In Relation to Time 73
Variation In Relation to Characteristics of Individuals: Sociodemographics 76
Variation In Relation to Other Characteristics of Individuals 77
Variation In Relation to Socially Shared Characteristics of Individuals or Environments 79
Why Do Some People Become Cannabis Dependent 80
When Others Do Not? 81
A History of Other Forms of Drug Dependence 83
ASP Disorder 83
Primary Socialization Theory 83
Religion, Religiosity, Spirituality 84
Parents and Parenting 85
Family History and Genetics 85
Directions for New Research 87
Mechanisms: Pathogenesis, Natural History, and Consequences of Cannabis Dependence 87
Early Stages 88
Natural History In Relation to Clinical Features 89
Consequences 90
Fetal Exposure 93
Prevention, Intervention, Amelioration, and Control 93
Future Directions 94
References 95

5 The Adverse Health and Psychological Consequences of Cannabis Dependence

WAYNE HALL AND NADIA SOLOWIJ

Assessing Health Effects of Chronic Cannabis Use 106
The Respiratory Risks of Cannabis Smoking 107
Chronic Cannabis Use and Respiratory Cancers 108
Chronic Cannabis Use and Brain Function 110
Chronic Cannabis Use and Cognitive Impairment 111
Accidental Injury and Chronic Cannabis Use 114
Contents

Cardiovascular Effects 115
Special Populations of Cannabis-Dependent Persons 116
  The Educational Consequences of Adolescent Cannabis Dependence 116
  The Gateway Hypothesis 117
  Psychosis and Schizophrenia 119
Conclusions 121
References 122

Part II: Interventions with Cannabis-Dependent Adults

6 Cognitive-Behavioral and Motivational Enhancement Treatments for Cannabis Dependence
ROBERT S. STEPHENS, ROGER A. ROFFMAN, JAN COPELAND AND WENDY SWIFT
MET Principles and Techniques 133
CBT Principles and Techniques 136
Combining MET and CBT Approaches 138
Group versus Individual Treatment 139
Issues in the Treatment of Cannabis Dependence 140
Review of Treatment-Outcome Studies 142
Mechanisms of Change 146
Summary and Future Directions 148
References 150

7 Contingency-Management Interventions for Cannabis Dependence
ALAN J. BUDNEY, BRENT A. MOORE, STACEY C. SIGMON
AND STEPHEN T. HIGGINS
  Conceptual Framework 155
  Basic Principles 156
  Efficacy of CM 156
  Principles of Application 157
  Effective Implementation 159
Initial Treatment Study for a CM Voucher Program for Cannabis Dependence 161
  Study Design 161
  Participants 161
  Treatments 162
  Results 164
Using CM to Engage Probation-Referrred Marijuana Abusers in Treatment 166
Contents

Cannabis as a Secondary Drug of Abuse 167
Cannabis Abuse among Cocaine Abusers 167
Cannabis Abuse in the Methadone Clinic 168
Cannabis Use in Individuals with Severe Psychiatric Illness 169
CM in the Treatment of Adolescent Marijuana Abusers 170
Concluding Comments 170
References 172

8 The Marijuana Check-Up
ROBERT S. STEPHENS AND ROGER A. ROFFMAN
Implementing a MCU 180
Marketing the MCU 180
The Assessment and Personal Feedback Report 183
Motivational Interviewing 186
Clinical and Ethical Issues 187
A Controlled Trial of the MCU 190
Conclusions and Future Directions 199
References 200

9 Guided Self-Change: A Brief Motivational Intervention for Cannabis Abuse
LINDA C. SOBELL, MARK B. SOBELL, ERIC F. WAGNER, SANGEETA AGRAWAL AND TIMOTHY P. ELLINGSTAD
Prevalence 204
GSC Treatment 205
Background and Development of the Approach 205
Major Principles and Techniques of GSC 206
Applying GSC Treatment to Cannabis Users 208
A Controlled Treatment Trial Using GSC with Cannabis Users 211
Participants 212
Assessment 212
Treatment Description for Individual and Group Treatment Formats 213
Within Treatment Data, Retention Rates, and Follow-up 214
Cannabis Abuser Characteristics at Pre-treatment 215
GSC Treatment Outcomes 215
Conclusions and Recommendations 217
References 218
10 Supportive–Expressive Psychotherapy for Cannabis Dependence
BRIN F. S. GRENYER AND NADIA SOLOWIJ

Empirical Bases  226
SE Psychotherapy Techniques  227
   Supportive Techniques  228
   Expressive Techniques  229
   Identifying CCRTs  229
Dealing with Cognitive Deficits from Long-Term Use  230
Typical Sequencing of Treatment Components  231
Therapist Training  232
Studies of SE Psychotherapy with Cannabis Users  233
Illustrative Case Study  237
Conclusion and Future Directions  239
References  240

Part III: Interventions with Cannabis-Dependent Adolescents and Young Adults

11 The Cannabis Youth Treatment Study: The Treatment Models and Preliminary Findings
GUY DIAMOND, JODI LECKRONE, MICHAEL L. DENNIS AND SUSAN H. GODLEY

Introduction  247
Description of the Interventions  249
   MET/CBT5 (Sampl & Kadden, 2001)  249
   MET/CBT12 (Webb et al., 2002b)  251
   FSN plus MET/CBT12 (Hamilton et al., 2001)  252
   ACRA (Godley et al., 2001a)  253
   MDFT (Liddle, 2002)  255
Overview of CYT Study  258
   Study Design  258
   Analytic Procedure  259
   Participants  260
   Clinical Procedures  262
   Results  263
Cost-Effectiveness Analysis  265
Therapist’s Response to Manualized Treatment  266
Conclusions and Recommendations  267
References  269
### 12 The Teen Cannabis Check-up: Exploring Strategies for Reaching Young Cannabis Users

**James P. Berghuis, Wendy Swift, Roger A. Roffman, Robert S. Stephens and Jan Copeland**

- **Epidemiology of Adolescent Cannabis Use** 275
- **Negative Consequences of Adolescent Cannabis Use** 276
- **Intervention Research with Adolescents** 277
- **Developmental Issues in Designing Interventions for Adolescents** 279
- **The Check-up: Tailoring an Intervention for Adolescent Cannabis Users** 280
- **US and Australian Studies in Progress** 282
- **Recruitment Approaches** 283
- **Characteristics of Enrolled Teens** 284
- **Outcomes** 286
- **Perceptions of the Intervention** 287
- **Issues in Implementing a Check-up Intervention** 287
- **Working with Persons Concerned About an Adolescent** 287
- **Marketing Strategies** 288
- **Confidentiality and Consent** 289
- **Coercion** 289
- **Counselor Training and Quality Assurance** 290
- **Summary and Discussion** 290
- **References** 292

### 13 Engaging Young Probation-Referred Marijuana-Abusing Individuals in Treatment

**Kathleen M. Carroll, Rajita Sinha and Caroline Easton**

- **Why Target Young Adult Marijuana Users?** 297
- **Why Target Marijuana Users Referred by the Legal System?** 298
- **Why Evaluate a Motivational Enhancement Approach?** 298
- **Why Evaluate a Contingency Management Approach?** 300
- **Description of the Interventions** 300
  - **MET** 300
  - **MET and CM** 301
  - **Therapists and Training** 302
- **Review of Study** 304
  - **Results** 305
  - **Conclusions and Future Directions** 305
- **Summary** 308
- **References** 309
Part IV: Policy

14 The Policy Implications of Cannabis Dependence
WAYNE HALL AND WENDY SWIFT

Introduction 315
Key Features of the Epidemiology of Cannabis Use and Dependence 316
Does Cannabis Dependence Require a Policy Response? 316
Public Health System Responses to Cannabis Dependence 318
Public Health Policies for Cannabis 319
Public Education about Cannabis Dependence 320
Screening and Brief Intervention for Hazardous Cannabis Use 321
Specialist Treatment for Cannabis Dependence 322
Withdrawal Management 323
Dealing with Comorbid Substance Disorders 323
Dealing with Comorbid Mental Disorders 324
Responding to Adolescent Cannabis Dependence 325
Cannabis Dependence and the Cannabis Policy Debate 326
Dependence and Therapeutic Cannabinoid Use 326
Possible Effects of Changes in the Legal Status of Cannabis Use 327
Decriminalization of Cannabis Use 328
De Facto Legalization of Cannabis Use 328
De Jure Legalization of Cannabis Use 329
Conclusions 330
References 331

Part V: Conclusion

15 The Nature, Consequences and Treatment of Cannabis Dependence: Implications for Future Research and Policy
ROBERT S. STEPHENS AND ROGER A. ROFFMAN

What is the Nature of Cannabis Dependence? 343
What are the Consequences of Cannabis Dependence? 348
Is the Treatment of Cannabis Dependence Effective? 350
What Should the Policy on Cannabis Dependence be? 354
Conclusion 355
References 355

Index 357
Contributors

Sangeeta Agrawal, M.Sc
Research Analyst/Instructor
College of Nursing
University of Nebraska
Omaha, Nebraska, USA

James C. Anthony, Ph.D
Chairperson
Department of Epidemiology
College of Human Medicine
Michigan State University
East Lansing, Michigan, USA

Thomas F. Babor, Ph.D, M.P.H
Department of Community Medicine and Health Care
School of Medicine
University of Connecticut Health Center
Farmington, Connecticut, USA

James Berghuis, Ph.D
Community Health Centers of King County
Kent, Washington, USA

Alan J. Budney, Ph.D
Department of Psychiatry
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA

Kathleen Carroll, Ph.D
Department of Psychiatry
Director of Psychosocial Research
Division of Substance Abuse
School of Medicine
Yale University
New Haven, Connecticut, USA

Jan Copeland, Ph.D
National Drug and Alcohol Research Centre
School of Community Medicine and Public Health
University of New South Wales
Sydney, NSW, Australia

Michael L. Dennis, Ph.D
Chestnut Health Systems
Bloomington, Illinois, USA

Guy Diamond, Ph.D
Children’s Hospital of Philadelphia and the University of Pennsylvania
Philadelphia, Pennsylvania, USA

Caroline Easton, Ph.D
Department of Psychiatry
School of Medicine
Yale University
New Haven, Connecticut, USA
Contributors

Timothy P. Ellingstad, Ph.D
Clinical Psychologist
Aurora Behavioral Health
Burlington, Wisconsin, USA

Susan H. Godley, Rh.D
Chestnut Health Systems
Bloomington, Illinois, USA

Brin Grenyer, Ph.D
Illawarra Institute for Mental Health and
Department of Psychology
University of Wollongong
NSW, Australia

Wayne Hall, Ph.D
Institute for Molecular Bioscience
University of Queensland
St Lucia, Queensland, Australia

Stephen T. Higgins
Human Behavioral Pharmacology Laboratory
University of Vermont
Burlington, Vermont, USA

Jodi Leckrone, M.Ed
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania, USA

Aron H. Lichtman, Ph.D
Department of Pharmacology and Toxicology
Virginia Commonwealth University
Richmond, Virginia, USA

Billy R. Martin, Ph.D
Department of Pharmacology and Toxicology
Virginia Commonwealth University
Richmond, Virginia, USA

Brent A. Moore, Ph.D
Department of Psychiatry
Yale School of Medicine
New Haven, Connecticut, USA

Roger A. Roffman, D.S.W
School of Social Work
University of Washington
Seattle, Washington, USA

Sam Schwartz, M.S.W
School of Social Work
University of Washington
Seattle, Washington, USA

Stacey C. Sigmon
Department of Psychiatry
University of Vermont
Burlington, Vermont, USA

Rajita Sinha, Ph.D
Department of Psychiatry
School of Medicine
Yale University
New Haven, Connecticut, USA

Linda C. Sobell, Ph.D
Center for Psychological Studies
Nova Southeastern University
Ft. Lauderdale, Florida, USA

Mark B. Sobell, Ph.D
Center for Psychological Studies
Nova Southeastern University
Ft. Lauderdale, Florida, USA

Nadia Solowij, Ph.D
Illawarra Institute for Mental Health and
Department of Psychology
University of Wollongong
NSW, Australia
Contributors

Robert Stephens, Ph.D
Department of Psychology, Virginia Polytechnic Institute and State University
Blacksburg, Virginia, USA

Wendy Swift, Ph.D
National Drug and Alcohol Research Centre
School of Community Medicine and Public Health
University of New South Wales
Sydney, NSW, Australia

Eric F. Wagner, Ph.D
College of Health and Urban Affairs
Florida International University
North Miami, Florida, USA
Acknowledgments

We have many to thank for the contributions they have made to our research on cannabis dependence and to the preparation of this volume. Professors Tom Babor and Wayne Hall offered invaluable advice as we began to plan the book’s purposes and consider its potential audience. Professor Griffith Edwards, editor of the IRMA series, warmly welcomed our inquiry about the prospect of a book with this theme and then helped us to refine our early ideas concerning its contents. We benefited greatly by Professor Edwards’ tutelage and encouragement.

Richard Barling, Pauline Graham, and Jayne Aldhouse at Cambridge University Press offered enthusiastic support along the way and helped us to understand and appreciate the requirements of book production. We are privileged in having our work put into print by this highly esteemed publishing house.

We very much appreciate having had the opportunity to work with the Project Management staff at Charon Tec where the copy editing, typesetting, and correspondence with authors concerning editing queries were completed.

The contributors to this volume, leaders in cannabis studies in their respective disciplines, willingly trekked with us by preparing brief concept pieces concerning their chapters, moving from concept to outline, attending to our feedback, completing initial drafts, and again being responsive to our requests and suggestions in preparing the final manuscripts. We appreciate the quality of their scholarship and their patience with us as co-editors.

Over a number of years, many faculty, staff, and student colleagues at the University of Washington and Virginia Polytechnic Institute and State University played key roles in implementing the intervention trials discussed in Parts II and III. We are particularly grateful to Julia McGraw and McKenzie Winters who edited each chapter to meet the publisher’s citation and formatting requirements.

Our colleague and friend, Professor Alan Marlatt, was gracious in agreeing to read the book and offer his reflections in the Foreword. As is true for many
who study addictive disorders, we have been inspired by Alan’s creativity and
enormously influential work.

We wish to express our gratitude to the National Institute on Drug Abuse and
to the Center for Substance Abuse Treatment for the funding that has supported
our cannabis intervention trials. Finally, as is the case with all who study
human behavior, we are indebted to the participants in these trials for permit-
ting us to learn through their experiences.
Executive Summary

At the time of this volume’s completion in 2005, important advances had been made in understanding the etiology and epidemiology of cannabis dependence, describing its neuropharmacology and the physiology of the endocannabinoid system, identifying associated consequences that impact health and behavior, and developing and evaluating the relative effectiveness of a variety of counseling interventions for adults and adolescents with cannabis abuse disorders. Many of these advances built on recent progress in the neuroscience of the endogenous cannabinoid system, in more precise classification and diagnostic paradigms for drug use disorders, and in the development and testing of theories of human behavior change.

This volume is organized into four sections. Part I focuses on the nature of cannabis dependence, with chapters devoted to the history of the concept, diagnosis and classification, pharmacology and physiology, epidemiology, and adverse health and behavioral consequences. Part II discusses intervention trials based on several theoretical frameworks with cannabis-dependent adults. Therapeutic interventions with adolescents and young probation-referred adults, again drawing from similar theories of behavior change, are the focus of Part III. Policy considerations vis-à-vis cannabis dependence are the focus of Part IV, and the volume concludes in Part V with commentary that offers a summary and synthesis of what is currently known about dependence on cannabis. Below we have listed some of the primary conclusions that can be drawn from each of the chapters in these areas.

Part I: The Nature of Cannabis Dependence

Our understanding of the existence and nature of cannabis dependence has long been shaped by social and political forces that have polarized opinions and policies. The explosion of scientific research on the phenomena in recent years is
starting to build a consensus that a small but significant subset of cannabis users develops a dependence syndrome, many of whom need treatment.

Standard nomenclatures and classification systems, such as ICD and DSM, provide reliable and valid operational criteria for cannabis dependence. With these tools it has become possible to characterize participants in clinical research and to obtain population estimates of cannabis use disorders.

The elucidation of the structure of delta-9-tetrahydrocannabinol, the discovery of anandamide and cannabinoid receptors, and the synthesis of cannabinoid agonists and antagonists support the existence of an endocannabinoid system in the central nervous system that is believed to modulate cannabis dependence.

There is considerable evidence from animal and human models that physical dependence on cannabis, as identified by tolerance and withdrawal phenomena, can be induced via prolonged exposure.

Current research is focused on which regions of the brain mediate physical dependence and the nature of the underlying cellular mechanisms of action. Research focusing on the CB1 receptor and the action of antagonists such as SR141716A in precipitating withdrawal has potential relevance to the eventual development of pharmacotherapies for the treatment of cannabis dependence.

In the USA, within the first 24 months of cannabis use initiation, 2–4% of users (or 50–80 people each day) progress to cannabis dependence. Annually, that amounts to 20,000–30,000 individuals. Cannabis dependence occurs in 1 in 9 to 11 individuals who have ever used the drug, and 11–16% (1.6–2.3 million individuals) of the 14 million current users.

Converging evidence from the USA, Australia, and New Zealand, although limited due to sample differences, supports an estimate that 1 in 6 or 7 adolescents and young adult cannabis users become cannabis dependent by their early to mid-twenties: USA: 1 in 6–7 (16%); New Zealand: 1 in 7 or 7.5 (13–14%); Australia: 1 in 6 (16.7%). It is uncertain why a lower risk is reflected in data from Germany: 1 in 20–25 (4–5%).

More than 90% of cannabis dependence cases in the USA occur between the ages of 15 and 35 years, typically within the first 10 years of use. Male cannabis users have more commonly become dependent on the drug, although the gender gap has lessened. With reference to race and ethnicity, Native Americans disproportionately report persistent cannabis use, and there is some evidence that young African Americans and young Hispanic males had disproportionately greater increases in the prevalence of cannabis use disorders in the 1990s.

Risk factors for cannabis dependence may include mood disorders, residing in neighborhoods with greater magnitudes of daily users, and having a history
of alcohol use disorder. Common vulnerability traits that contribute to cannabis dependence, as well as other disorders, may result from either genetic or environmental factors or their interaction. In the future, it is likely that studies of community and family contextual effects, when examined along with individual-level risk factors, will further our understanding of the etiology of cannabis dependence.

The Adverse Health and Psychological Consequences of Cannabis Dependence

Understanding of the health consequences of cannabis dependence is based on studies with heavy users rather than with the more specific population of those who are cannabis dependent.

Increased risk of chronic bronchitis and histopathological changes in the respiratory system that may precede malignancy are related to the method of administration (smoking). There is some evidence that heavy cannabis smokers are at greater risk for infectious diseases such as pneumonia. Clarification of the relationship between cannabis smoking and cancer risk will necessitate larger cohort studies and larger case control studies.

Some research supports the existence of subtle types of cognitive impairment (attention; memory; and impaired verbal learning, retention, and retrieval) in long-term heavy cannabis users. Competing explanations for these findings include residual effects from recent use, residues of the drug that are stored in the body after abstinence is attained, and the nervous system’s re-adaptation to abstinence following chronic exposure. Research on the recovery of cognitive functioning following cessation is needed. Functional brain imaging studies will be important in future investigations of cannabis-related cognitive deficits.

The risk of cannabis dependence appears to be increased in those who initiate use at earlier ages. Early use also has been shown to be associated with earlier withdrawal from school, earlier sexual activity, pregnancy during adolescence, unemployment, and leaving the family home early. Adolescents who smoke cannabis heavily appear to be at increased risk of using “harder drugs.” The causal relationship of cannabis use to these outcomes is not well established because young users often have multiple risk factors.

Subgroups of cannabis-dependent persons at increased health risk include:

- adults with cardiovascular disease who may precipitate myocardial infarctions by smoking cannabis;
- adolescents whose school performance and psychosocial development may be adversely affected and who may be at increased risk of using other illicit drugs;
persons with schizophrenia and other psychoses whose illnesses may be exacerbated by continued use of cannabis;

persons with a family history of psychoses in whom regular cannabis use may precipitate the onset of a psychosis.

Part II: Interventions with Cannabis-Dependent Adults

A variety of treatments for cannabis-dependent adults have been tested in randomized controlled trials. All are adaptations of therapeutic models that have shown efficacy in the treatment of alcohol, tobacco, or other drug problems. Chapters in this and the following section present the theoretical background, treatment techniques, and issues in the adaptation and implementation of these approaches with cannabis-dependent adults, as well as the results of treatment-outcome studies completed to date.

Motivational enhancement therapy (MET) and cognitive-behavioral therapy (CBT) have received the most research attention and have often been combined with MET strategies used in early sessions and CBT strategies in later sessions. Results have been uniformly positive in showing reduced marijuana use and associated problems following treatment, but long-term abstinence rates are typically less than 20% and relapse is common.

There is little evidence that either MET or CBT is superior to the other and both are effective in either group or individual formats.

In several trials, very brief (2–4 sessions) MET interventions produced significant reductions in cannabis use but there is some evidence that longer (9–14 sessions) MET/CBT interventions yield better outcomes.

Contingency management (CM), involving the delivery of monetary incentives for urine-verified abstinence, showed promise in increasing rates of continuous abstinence during treatment, but longer-term outcomes after the incentives are discontinued are not yet known. Other novel adaptations of the CM approach are being studied.

A Marijuana Check-Up (MCU) designed to appeal to adult cannabis users who were ambivalent about change or treatment attracted a sample of daily users. They differed little from treatment seekers with the exception of less readiness to change and somewhat fewer self-reported negative consequences. The two-session MET intervention resulted in a greater reduction in the frequency of cannabis use during the follow-up period compared to control conditions. Reductions in use were small in absolute terms, but the approach showed promise in reaching another segment of cannabis-dependent adults who may benefit from treatment.
Supportive–Expressive (SE) psychotherapy, emphasizing the importance of effective interpersonal relationships in overcoming addiction, led to greater rates of abstinence than a single session of advice. Process data indicated that SE led to changes in interpersonal effectiveness that at least partially accounted for the greater abstinence.

Part III: Interventions with Cannabis-Dependent Adolescents and Young Adults

There is a dearth of controlled treatment-outcome studies with adolescent or young adult cannabis abusers. These groups are at different stages of development and pose different treatment issues compared to adults. Most are coerced into treatment rather than seeking it voluntarily.

The Cannabis Youth Treatment study, a large multi-site investigation, compared five interventions of different durations and intensities. Therapeutic models included various combinations of MET, CBT, and family therapy. Although there were few differences in outcomes between treatments, overall results indicated substantial reductions in cannabis use and problems during the 12 months of follow-up. Analyses addressed issues of comorbidity, retention in treatment, differential response to treatment, and cost-effectiveness.

Two adaptations of the “check-up” model as a method for reaching teenage cannabis users on a voluntary basis were tested in the USA and Australia. The respective projects used somewhat different methods of recruiting participants, but both delivered a two-session MET intervention. Results from these uncontrolled studies showed substantial reductions in cannabis use and positive perceptions of the interventions supporting further development and testing.

An intervention combining MET with monetary incentives for attending treatment sessions increased treatment attendance in young adults referred by probation departments relative to MET alone. Greater reductions in marijuana use were not observed as a consequence, however.

Part IV: Policy

The Policy Implications of Cannabis Dependence

Public education of the risks of cannabis dependence must present credible consequences of heavy use in order to avoid being rejected.

Prevention efforts should include opportunistic (e.g., primary care) and targeted screening and brief interventions in vulnerable populations. Delivery
of more extensive treatment services to meet the needs of cannabis-dependent individuals with comorbid substance abuse or mental health disorders in specialized treatment agencies would provide a more complete continuum of care.

Studies of decriminalization in several countries yield conflicting conclusions regarding effects on rates of cannabis use and do not address effects on heavy use or dependence.

The prevalence of cannabis dependence may increase if legal sanctions for use were decreased or eliminated because lower price and greater availability would result in more people using cannabis regularly and for longer periods in their lives. Greater numbers of individuals, therefore, may experience health and psychological problems, including cannabis dependence.

However legalization would allow for a regulated cannabis market that would permit more widespread harm minimization educational activities and the development of social norms favoring moderation and stigmatizing excess. Adequate data do not exist to predict the net result of such changes in policy.

Part V: Conclusion

Cannabis dependence exists and is associated with negative consequences that affect millions of users. Many of these individuals need and want help in overcoming dependence.

Despite the apparent validity of a dependence syndrome, the negative consequences of cannabis dependence may not be as severe as for many other drug dependencies. This relative lack of negative consequences may fuel low motivation for change and undermine the effectiveness of treatment interventions.

More research on the nature and consequences of cannabis dependence is needed to inform policy decisions that can prevent its occurrence. More research is also needed on treatment approaches that build and sustain motivation for change.
Foreword

Marijuana continues to be a hot topic in the news. At the time of this writing (July, 2005), The Seattle Times has published numerous stories about the “green plant” and controversies surrounding its use and potential for abuse. Many featured articles described the debate about medical marijuana and the US Supreme Court’s recent decision that federal drug charges can be applied to users and distributors of marijuana even in those states that passed local laws approving cannabis use as a treatment for several disorders (e.g., reduction of nausea associated with chemotherapy, appetite enhancement in the treatment of AIDS, lowering intra-ocular pressure in the treatment of glaucoma, and so on). As Washington is one of the states that voted to approve the medical use of marijuana, press coverage has been sympathetic to the plight of patients who may now be denied access to the healing herb. Based on this press coverage, most readers (as judged by letters to the Editor of the Seattle Times) were outraged by the Supreme Court decision, given the evidence that so many patients reported beneficial effects from smoking pot.

Other stories about marijuana that have been covered in the local press express criticism and concern over its use. Here in the Pacific Northwest, public officials have expressed outrage about the distribution of potent marijuana that has been smuggled into Washington and adjoining states from our Canadian neighbors to the north. Known as “B.C. bud,” this strong variety of marijuana is highly sought after by local smokers. Recently, several B.C. residents were arrested after they were discovered smuggling large quantities of B.C. bud through a sophisticated 360-foot tunnel buried under the Canada–USA border near Langley, B.C. The three men arrested were monitored in the underground pathway carrying hockey bags and garbage sacks containing 93 pounds of B.C. bud. Political tension between the two countries has also been exacerbated by the recent announcement by the mayor of Vancouver, B.C. that efforts would soon be made to decriminalize marijuana sales in the province and to
provide additional tax revenues as a result. Marijuana sales would be regulated in the same manner as tobacco and alcohol, according to the mayor. Public opinion sways back and forth on both sides of the border. Is marijuana use helpful (as a medicine) or harmful (as an addictive drug)? Confusion and debate continue about the potential for abuse and dependence among marijuana smokers. Some see it as a relatively benign substance compared to other drugs of abuse, while others see it as a “stepping stone” that leads to further illegal drug use.

Despite the continuing controversy and public ambivalence, one fact stands out clearly: marijuana is the most commonly used illicit drug in the world. In “A Closing Note” at the conclusion of Chapter 1 of the current volume, the authors cite a United Nations report issued in 2004 indicating that cannabis is the most widely used illicit drug worldwide “with an estimated 146.2 million people having consumed cannabis at least once in the previous 12-month period. Although this report suggested that the spread of drug abuse is losing momentum globally, the one notable exception was cannabis which was described as spreading at an accelerated pace.” According to a recent Research Report on Marijuana Abuse published by the National Institute on Drug Abuse (July, 2005), marijuana is also the most commonly used illicit drug in the US. The report concludes that more than 94 million Americans (40% of the population) aged 12 years and older have tried marijuana at least once. Data from the 2004 Monitoring the Future Survey, summarized in the NIDA report, indicated that 46% of high-school seniors had tried marijuana at some time and that 20% were current users. A study conducted by the National Institute of Justice’s Arrestee Drug Abuse Monitoring Program (also cited in the NIDA report) found that 57% of juvenile male and 32% of juvenile female arrestees tested positive for marijuana. The NIDA report also summarized findings from the 2003 National Survey on Drug Use and Health, indicating that an estimated 21.6 million Americans aged 12 or older were classified with substance dependence or abuse (9.1% of the total population); of the estimated 6.9 million Americans classified with abuse or dependence on illicit drugs, 4.2 million were dependent on or abused marijuana. In 2002, 15% of people entering drug abuse treatment programs reported that marijuana was their primary drug of abuse, according to the NIDA report. Epidemiological data described in the current book also indicates that many users are at risk for developing a diagnosis of cannabis dependence. Among current users (i.e., used at least once in the prior month), roughly 11–16% (1.6–2.3 million individuals) qualify for the diagnosis of cannabis dependence, as reported in Chapter 1.

Although marijuana may be less harmful in terms of health consequences and addiction potential compared to other illicit drugs (such as heroin or crystal meth) or licit substances (alcohol and tobacco), the information reported on the
high rates of use and associated risks for marijuana dependency represents a major public health challenge for health professionals. Surprisingly little information currently exists regarding treatment approaches for cannabis dependence. In response to this growing need, the present volume is both timely and relevant. As a colleague and friend of both Roger Roffman and Robert Stephens for many years, I congratulate them for their excellent work in co-editing this new book on cannabis dependence. They are both pioneers in the field of marijuana research and associated treatment and intervention programs. Together, they have invited an impressive list of authors to contribute their expertise and clinical experience to further our understanding of this important topic. As a result, they have brought together a wealth of information and insight that readers will find invaluable.

The fifteen chapters in this book are divided into five parts. Part I contains five chapters devoted to describing the nature of cannabis dependence. Chapter 1 (Roffman, Schwartz, and Stephens) provides a history of cannabis dependence themes that have appeared in the past and that continue to have influence on how this concept will be defined in the future. In Chapter 2, Babor provides an incisive overview of the diagnostic criteria for cannabis dependence, including its etiology, course, and natural history. The pharmacology and physiology of this dependency is presented in Chapter 3 (Lichtman and Martin), based on results from both animal and human studies that indicate a reciprocal relationship between cannabinoid and opioid systems in drug dependence. The epidemiology and etiology of cannabis dependence are reviewed in Chapter 4 by James Anthony, with a focus on recent evidence from field studies. In Chapter 5, the final chapter in this section, Hall and Solowij provide a review of evidence related to the adverse health and psychological consequences, with an emphasis on studies of long-term daily cannabis users.

Part II consists of five chapters devoted to treatment interventions for cannabis-dependent adults. Given the need for more information on evidence-based treatment approaches, the authors are to be commended for their cutting-edge empirical work and the presentation of treatment-outcome data in many of the chapters. Chapter 6 (Stephens, Roffman, Copeland and Swift) provides an overview of both cognitive-behavioral (e.g., relapse prevention) and motivational enhancement (e.g., motivational interviewing) treatment approaches, both of which have been relatively effective and well received by adult clients. Another promising intervention, contingency management, is described in Chapter 7 (Budney, Moore, Signon and Higgins) and has been found effective in enhancing initial abstinence rates in treatment-outcome studies. For adult marijuana users who have questions or concerns about their use, the “Marijuana Check-up”
described in Chapter 8 by Stephens and Roffman is highly recommended, consisting of a brief two-session assessment and feedback intervention patterned after the “Drinkers’ Check-up” designed to promote change in alcohol users who are unlikely to seek formal treatment. Another treatment approach first developed for use with problem drinkers and now modified as a brief motivational intervention for cannabis abuse is guided self-change, described in Chapter 9 (Sobell, Sobell, Wagner, Agrawal and Ellingstad). This intervention may be particularly helpful for cannabis users with less severe problems or who are ambivalent about treatment goals (reduced use versus abstinence). In Chapter 10, Grenyer and Solowij describe supportive–expressive psychotherapy, a dynamic approach that emphasizes the importance of effective interpersonal relationships as an important mediating factor in treatment outcome.

Three chapters are presented in Part III, each describing promising interventions for adolescents and young adults. Chapter 11 (Diamond, Leckrone, Dennis and Godley) provides preliminary findings from the Cannabis Youth Treatment Study that evaluated the impact of five brief intervention programs, including various combinations of cognitive-behavioral, motivational enhancement, family support networks, a community reinforcement approach, and multidimensional family therapy in the outpatient treatment of adolescents with marijuana problems. Preliminary results indicate that these brief interventions can be helpful for many adolescent clients; treatment was found to be effective overall (although few differences were reported across the different treatment conditions), showing good retention rates and lower costs. The “Teen Cannabis Check-Up” program for adolescent clients, similar in content and format to the check-up program for adult users, is described in Chapter 12 (Berghuis, Swift, Roffman, Stephens and Copeland), with encouraging results in terms of reduced cannabis use among teens studied in both Australia and the USA. The final chapter (Chapter 13) in this section presents promising findings in the treatment of young probation-referred marijuana-abusing individuals (Carroll, Sinha, and Easton), in which motivational enhancement therapy and contingency management were evaluated.

Part IV consists of a single chapter (Chapter 14) outlining the public policy implications of cannabis dependence, and discussing implications for both the public health sector and the specialized treatment arena. Hall and Swift also discuss additional hot policy topics, including cannabis decriminalization. Part V concludes the book with a final wrap-up chapter by the editors (Chapter 15 by Stephens and Roffman), integrating the treatment findings presented in the preceding chapters and discussing implications for future research. Although they conclude that reductions in cannabis use resulting from treatment were often substantial (consistent with a harm-reduction approach), long-term abstinence
rates remain relatively low (80% relapse rate). Clearly there is still a room for improvement in our treatment approaches for cannabis dependence, but the material presented throughout this valuable text should pave the way for future advances in the field. Hats-off and thumbs-up to Roger Roffman and Robert Stephens for opening up the highway!

G. ALAN MARLATT
University of Washington